Journal: PLoS ONE

Article Title: Analysis of the In Vivo Turnover of CD4+ T-Cell Subsets in Chronically SIV-Infected Sooty Mangabeys

doi: 10.1371/journal.pone.0156352

Figure Lengend Snippet: The mean (±SEM) percent Ki67+ (A+B) and percent BrdU+ (C+D) of peripheral blood CD4+ (A+C) and CD8+ (B+D) T-cells were assessed longitudinally by flow cytometry in both uninfected (black squares) and infected (red circles) animals. p = NS between infected and uninfected controls at all timepoints for all populations (Mann-Whitney U). Shaded area represents BrdU administration period. Data points are shown only for animals above which 100 events were collected for the parent population.

Article Snippet: Mouse-derived monoclonal antibodies directed against the following antigens were used at titration-assessed volumes as follows: BrdU (clone 3D4, 20uL), CCR5 (3A9, 10uL), CD3 (SP34-2, 5uL), CD8 (SK1, 5uL), CD62L (SK11, 10uL), Ki67 (B56, 20uL) from BD Biosciences Pharmingen, CD4 (OKT4, 5uL) from BioLegend, CD28 (CD28.2, 10uL) from Beckman-Coulter, and CD95 (DX2, 10uL) from eBioscience.

Techniques: Flow Cytometry, Infection, MANN-WHITNEY

Journal: PLoS ONE

Article Title: Analysis of the In Vivo Turnover of CD4+ T-Cell Subsets in Chronically SIV-Infected Sooty Mangabeys

doi: 10.1371/journal.pone.0156352

Figure Lengend Snippet: A-B. (±SEM) percent BrdU expression was assessed longitudinally by flow cytometry among CD4+ (A) and CD8+ (B) T N , T CM , T TM , T EM , and CCR5+ TM in uninfected (left) and SIV-infected (right) animals. C. Mean (±SEM) longitudinal Ki67 expression of CD4+ T N , T CM , T TM , T EM , and CCR5+ TM in uninfected (left) and SIV-infected (right) animals. p = NS between infected and uninfected controls at all timepoints for all populations (Mann-Whitney U). Shaded area represents BrdU administration period. Data points are shown only for animals above which 100 events were collected for the parent population.

Article Snippet: Mouse-derived monoclonal antibodies directed against the following antigens were used at titration-assessed volumes as follows: BrdU (clone 3D4, 20uL), CCR5 (3A9, 10uL), CD3 (SP34-2, 5uL), CD8 (SK1, 5uL), CD62L (SK11, 10uL), Ki67 (B56, 20uL) from BD Biosciences Pharmingen, CD4 (OKT4, 5uL) from BioLegend, CD28 (CD28.2, 10uL) from Beckman-Coulter, and CD95 (DX2, 10uL) from eBioscience.

Techniques: Expressing, Flow Cytometry, Infection, MANN-WHITNEY

Journal: Cancer Management and Research

Article Title: Treatment-Related Lymphopenia is Possibly a Marker of Good Prognosis in Nasopharyngeal Carcinoma: a Propensity-Score Matching Analysis

doi: 10.2147/CMAR.S456717

Figure Lengend Snippet: Comparison Between High and Low Lymphocyte Count Groups (Wilcoxon Test)

Article Snippet: The blood samples underwent treatment with six-color fluorescent monoclonal antibodies ( Supplementary Table 1 ), namely CD3-FITC, CD16+56-PE, CD45-PerCP-Cy5.5, CD19-APC, CD8-APC-cy7, and CD4-PE-cy7 (Beijing Tongsheng Shidai Biotechnology, Beijing, China).

Techniques: Comparison

Journal: Cancer Management and Research

Article Title: Treatment-Related Lymphopenia is Possibly a Marker of Good Prognosis in Nasopharyngeal Carcinoma: a Propensity-Score Matching Analysis

doi: 10.2147/CMAR.S456717

Figure Lengend Snippet: Correlations Between Baseline and Δ Values (N = 746)

Article Snippet: The blood samples underwent treatment with six-color fluorescent monoclonal antibodies ( Supplementary Table 1 ), namely CD3-FITC, CD16+56-PE, CD45-PerCP-Cy5.5, CD19-APC, CD8-APC-cy7, and CD4-PE-cy7 (Beijing Tongsheng Shidai Biotechnology, Beijing, China).

Techniques:

Journal: Cancer Management and Research

Article Title: Treatment-Related Lymphopenia is Possibly a Marker of Good Prognosis in Nasopharyngeal Carcinoma: a Propensity-Score Matching Analysis

doi: 10.2147/CMAR.S456717

Figure Lengend Snippet: Kaplan-Meier survival curves based on high and low baseline counts of CD8 + ( A and B ), total ( C and D ), and CD4 + ( E and F ) T cells.

Article Snippet: The blood samples underwent treatment with six-color fluorescent monoclonal antibodies ( Supplementary Table 1 ), namely CD3-FITC, CD16+56-PE, CD45-PerCP-Cy5.5, CD19-APC, CD8-APC-cy7, and CD4-PE-cy7 (Beijing Tongsheng Shidai Biotechnology, Beijing, China).

Techniques:

Journal: Cancer Management and Research

Article Title: Treatment-Related Lymphopenia is Possibly a Marker of Good Prognosis in Nasopharyngeal Carcinoma: a Propensity-Score Matching Analysis

doi: 10.2147/CMAR.S456717

Figure Lengend Snippet: Kaplan-Meier survival curves for patients in the high and low CD8 + T cell count ( A and B ) and CD4 + /CD8 + T cell ratio ( C and D ) groups after treatment.

Article Snippet: The blood samples underwent treatment with six-color fluorescent monoclonal antibodies ( Supplementary Table 1 ), namely CD3-FITC, CD16+56-PE, CD45-PerCP-Cy5.5, CD19-APC, CD8-APC-cy7, and CD4-PE-cy7 (Beijing Tongsheng Shidai Biotechnology, Beijing, China).

Techniques: Cell Counting

Journal: Cancer Management and Research

Article Title: Treatment-Related Lymphopenia is Possibly a Marker of Good Prognosis in Nasopharyngeal Carcinoma: a Propensity-Score Matching Analysis

doi: 10.2147/CMAR.S456717

Figure Lengend Snippet: Kaplan-Meier survival curves for patients in the high and low CD4 + ( A and B ), total ( C and D ), and CD8 + ( E and F ) T cell groups, based on Δ values.

Article Snippet: The blood samples underwent treatment with six-color fluorescent monoclonal antibodies ( Supplementary Table 1 ), namely CD3-FITC, CD16+56-PE, CD45-PerCP-Cy5.5, CD19-APC, CD8-APC-cy7, and CD4-PE-cy7 (Beijing Tongsheng Shidai Biotechnology, Beijing, China).

Techniques:

Journal: bioRxiv

Article Title: Balancing activation and costimulation of CAR tunes signaling dynamics and enhances therapeutic potency

doi: 10.1101/2022.03.01.482445

Figure Lengend Snippet: CD19-1XX CAR-T cells show better anti-tumor activity in a pancreatic tumor model in vivo. (a) Timeline of of CD19 CAR-T treatment in mouse model. (b) Panc-1 CD19+ -bearing mice were treated with 1 × 10 6 CD19 CAR-T cells as indicated and tumor burden (tumor volume) of mice was measured at indicated days (n=4 mice each group). For mouse experiments, Control, PBS. (c) Tumor tissue from mice treated with indicated CAR-T cells. (d) Tumor tissue from mice treated with indicated CAR-T cells was sliced and stained with antibodies against human CD4 and CD8 (n=4). The percentage of CD4 + (e) and CD8 + (f) T cells in tumor tissue from different groups of mice (n=4). All data are mean ± SEM.

Article Snippet: Anti-Human CD4 antibody (BD, Horizon, BUV395), anti-Human CD8 antibody (BD, Pharmin, APC-CY™7), anti-Human CD279(PD-1) antibody (Invitrogen, eBioscience, PE-Cyanine7), anti-Human CD223(LAG-3) antibody (Invitrogen, eBioscience,, Percp-efluor™710), anti-Human CD45RA antibody (Invitrogen, eBioscience, FITC), anti-Human CD62L antibody (Invitrogen, eBioscience, efluor450).

Techniques: Activity Assay, In Vivo, Staining

Journal: bioRxiv

Article Title: Balancing activation and costimulation of CAR tunes signaling dynamics and enhances therapeutic potency

doi: 10.1101/2022.03.01.482445

Figure Lengend Snippet: 1XX modification of AXL CAR enhance its anti-tumor activity in a melanoma tumor model. (a) Timeline of of AXL CAR-T treatment in mouse model. (b) A375-bearing mice were treated with 2.5 × 10 6 AXL CAR-T cells and tumor burden (tumor volume) of mice were measured at indicated days (n=4, 5, 5 mice in respective groups). Control, PBS. (c) Tumor tissue of mice treated with indicated CAR-T cells (n=4, 5, 5). (d) The weight of tumors from different groups of mice (n=4, 5, 5). Number of CAR-T(e), CD4 + CAR-T cells (f) and CD8 + CAR-T cells (g) in spleen of mice 20 days post CAR-T infusion (n=5, 3). (h-k) Phenotype of CAR-T cells in the spleen of mice 20 days after CAR-T infusion as demonstrated by the percentage of T CM (CD45RA - CD62L + ) and T EFF (CD45RA + CD62L - ) cells (n=5, 3). All data are mean ± SEM.

Article Snippet: Anti-Human CD4 antibody (BD, Horizon, BUV395), anti-Human CD8 antibody (BD, Pharmin, APC-CY™7), anti-Human CD279(PD-1) antibody (Invitrogen, eBioscience, PE-Cyanine7), anti-Human CD223(LAG-3) antibody (Invitrogen, eBioscience,, Percp-efluor™710), anti-Human CD45RA antibody (Invitrogen, eBioscience, FITC), anti-Human CD62L antibody (Invitrogen, eBioscience, efluor450).

Techniques: Modification, Activity Assay

Journal: BMC Neurology

Article Title: An immunotherapy effect analysis in Rasmussen encephalitis

doi: 10.1186/s12883-020-01932-9

Figure Lengend Snippet: Immunohistochemistry and flow cytometry of the brain tissues from differently treated patients with RE. Three multipanels show a representative pair of histopathological findings (magnification × 200) according to the different immunohistochemical staining and a table that summarized lymphocyte subpopulations in the brain tissues from patients corresponding to the histopathology. Immunostaining for CD45 (anti-CD45, leukocyte common antigen) identifies leukocytes in the brain tissue, and flow cytometry (FC) further determines their type. The distribution of CD19 + , CD3 + , CD4 + and CD8 + cells is expressed as a percentage from the lymphocytic gate (CD45 ++ cells and the side scatter corresponding to lymphocytes) and the activation as a percentage of HLADR + cells from CD4 + or CD8 + T cells (HLADR + /CD3 + CD4 + , HLADR + /CD3 + CD8 + ); several brain samples were measured in every patient and the median values and ranges are displayed. Immunoreactivity for astrocytic glial fibrillary acidic protein (anti-GFAP) reveals gliosis. a Low neuroinflammatory activity with scarce inflammatory cells and mild gliosis were found in P1, P2 and P4. Despite the same histopathological pattern, significant differences in CD3 + , CD8 + , HLADR + /CD3 + CD4 + and HLADR + /CD3 + CD8 + lymphocyte subpopulations were identified among these patients (Kruskal-Wallis and Dunn’s test in a post hoc analysis were employed; numbers in bold; details in the text). b High neuroinflammatory activity with lymphocytic infiltrates and severe gliosis was found in P3 and P5; a significantly lower percentage of HLADR + /CD3 + CD8 + in the brain tissue of P5 was identified (Mann-Whitney test). c Medium neuroinflammatory activity with isolated inflammatory cells and medium to severe gliosis in the brain tissue exerted P6 and P7; no significant differences in lymphocyte subpopulations were found (Mann-Whitney test)

Article Snippet: Lymphocyte subpopulations were evaluated using the following antibody mixtures: 1) CD3 FITC, HLADR PE, CD45 PerCP, CD4 PE-Cy7, CD19 APC, CD8 APC-Cy7, CD14 PB and 2) CD3 FITC, CD16 + CD56 PE, CD45 PerCP-Cy5.5, CD4 PE-Cy7, CD19 APC, CD8 APC-Cy7, HLADR PB (both Exbio, Prague, Czech Republic).

Techniques: Immunohistochemistry, Flow Cytometry, Immunohistochemical staining, Staining, Histopathology, Immunostaining, Activation Assay, Activity Assay, MANN-WHITNEY, Isolation